226950 — OliX Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual cashflow statement for OliX Pharmaceuticals, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-19,385	-30,278	-21,888	-19,102	-40,659
Depreciation
Amortisation
Non-Cash Items	4,219	7,592	-1,945	3,203	11,624
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	10,266	2,002	-8,925	-7,912	-1,637
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-3,759	-19,054	-30,683	-21,168	-28,045
Capital Expenditures	-1,162	-26,285	-2,535	-9,068	-14,080
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-30,258	41,758	-52,229	43,435	15,053
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-31,420	15,473	-54,764	34,366	974
Financing Cash Flow Items	-55.2	-3.53	-166	-128	-15.3
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	41,660	26,555	56,048	-6,110	18,541
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	6,374	23,008	-29,406	7,052	-8,099